Product Information
OLMESARTAN MEDOXOMIL 40 MG TAB is a generic product labeled by Rising Pharma Holdings Inc., priced at $0.1110 per EA under NDC 64980060309. Its NADAC has been published 113 times since Aug 7, 2024.
FDA first approved this application on May 18, 2020. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
40 mg/1
Manufacturer
Rising Pharma Holdings Inc.NDC
64980060309
Classification
Generic
Dosage Form
TABLET, COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
OLMESARTAN MEDOXOMILApproval Type
Generic (ANDA)
FDA Application
ANDA208659FDA Approved
5/18/2020
TE Code
AB
On Market Since
3/30/2024
Pharmacological Classes
Price Statistics
The NADAC for OLMESARTAN MEDOXOMIL 40 MG TAB has been published 113 times since Aug 7, 2024, and over the history we have for it it has declined 6.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1110 per EA |
|---|---|
| All-time high | $0.1340 (Oct 16, 2024) |
| All-time low | $0.1083 (Aug 19, 2026) |
| 52-week high | $0.1235 |
| 52-week low | $0.1083 |
| Median price | $0.1224 |
| Average price | $0.1205 |
| Largest weekly change | -13.7% (Nov 20, 2024) |
| Weeks tracked | 113 |
| Tracking since | Aug 7, 2024 |
Generic Alternatives
The matcher finds 7 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 1% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Rising Pharma Holdings Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
olmesartan medoxomil market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Angiotensin 2 Receptor Blocker class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of OLMESARTAN MEDOXOMIL 40 MG TAB?
The current National Average Drug Acquisition Cost (NADAC) for OLMESARTAN MEDOXOMIL 40 MG TAB, manufactured by Rising Pharma Holdings Inc., is $0.1110 per EA (NDC 64980060309), effective Sep 30, 2026.
How has the price of OLMESARTAN MEDOXOMIL 40 MG TAB changed over time?
Over the history we have for it, the NADAC for OLMESARTAN MEDOXOMIL 40 MG TAB has declined 6.1%. It has been tracked across 113 weekly CMS publications since Aug 7, 2024.
What are the highest and lowest recorded NADAC prices for OLMESARTAN MEDOXOMIL 40 MG TAB?
Since Aug 7, 2024, the NADAC for OLMESARTAN MEDOXOMIL 40 MG TAB has ranged from a low of $0.1083 (Aug 19, 2026) to a high of $0.1340 (Oct 16, 2024), with a median of $0.1224 per EA.
Are there cheaper alternatives to OLMESARTAN MEDOXOMIL 40 MG TAB?
Yes. 7 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, OLMESARTAN MEDOXOMIL 40 MG TAB, is $0.1101 per EA — about 1% below OLMESARTAN MEDOXOMIL 40 MG TAB.
Who manufactures OLMESARTAN MEDOXOMIL 40 MG TAB?
OLMESARTAN MEDOXOMIL 40 MG TAB (NDC 64980060309) is labeled by Rising Pharma Holdings Inc., and CMS classifies it as a generic product.